Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Transdermally absorbed medicine comprising adjuvant-containing pharmaceutical microparticle and adjuvant-containing water for skin use

A technology for pharmaceutical excipients and drugs, which is used in medical preparations containing active ingredients, skin diseases, drug combinations, etc., can solve the problems of unstable particles and inability to guarantee the Ostwald ripening of particle suspensions, and achieves The effect of reducing waste and ensuring suspension stability

Inactive Publication Date: 2012-05-30
TIANJIN JINYAO GRP
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] How to solve the problem of particle instability in microparticle suspensions has always been one of the problems to be solved in pharmacy, but no matter whether by adding excipients or improving the particle structure, there is no guarantee that microparticle suspensions will not appear Osmos during storage. Twald ripening, especially with multiple uses of dermal suspensions, is more likely to occur

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Transdermally absorbed medicine comprising adjuvant-containing pharmaceutical microparticle and adjuvant-containing water for skin use
  • Transdermally absorbed medicine comprising adjuvant-containing pharmaceutical microparticle and adjuvant-containing water for skin use
  • Transdermally absorbed medicine comprising adjuvant-containing pharmaceutical microparticle and adjuvant-containing water for skin use

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0040] 1. Preparation of drug particles for transdermal absorption

[0041] The capsules packed with the drug microparticles obtained in Examples 1 to 10 are plant capsules, and the capsules are sealed and packaged with aluminum foil blisters after packing. The water containing auxiliary materials obtained in Examples 11 and 12 is sealed and packed in ampoules.

Embodiment 1

[0043] Dissolve 1g of hydrocortisone in ethanol, filter, sterilize, spray-dry the filtrate, micronize the particle size to 3μm, mix with 1.5g crystalline lactose with a particle size of 30μm, pass through a 200-mesh sieve for 3 times and mix well Finally, it is divided into No. 2 capsules, and each capsule contains 10 mg of hydrocortisone. Electron microscope observation shows that the drug particles are spherical.

[0044] The process conditions are: the inlet temperature is 100°C, the outlet temperature is 70°C, the air flow rate is 90%, the inner diameter of the nozzle outlet is 0.1cm, the air flow rate of the nozzle is 800ml / min, and the injection speed is 50mL / h

Embodiment 2

[0046] Dissolve 1 g of triamcinolone acetonide acetate in ethanol, filter, spray-dry the filtrate, micronize the particle size to 3 μm, mix with 15 g of crystalline lactose with a particle size of 30 μm, and then use a 200-mesh sieve to mix 3 times and then sterilize. Pack into No. 2 capsules, each capsule contains 1 mg of triamcinolone acetonide acetate. Electron microscope observation shows that the particles are spherical.

[0047] The process conditions are as follows: inlet temperature is 105°C, outlet temperature is 70°C, air flow rate is 90%, nozzle outlet inner diameter is 0.1cm, nozzle air flow rate is 800ml / min, and sample injection speed is 50mL / h.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
Login to View More

Abstract

The invention relates to a transdermally absorbed medicine comprising adjuvant-containing pharmaceutical microparticles and adjuvant-containing water for skin use, which is consisted of an individually-packaged skin pharmaceutical preparation that contains one or more solid pharmaceutical adjuvants, is insoluble in water and has a D90 particle size of 0.1-10 mum, and individually-packaged water containing one or more water-soluble pharmaceutical adjuvants.

Description

Technical field: [0001] The invention relates to a medicine for skin, which is composed of separately packaged medicine for skin containing one or several auxiliary materials for skin medicine and hardly soluble in water, and water containing the auxiliary materials in the separate package. Background technique: [0002] Skin inflammations such as eczema, allergic dermatitis, atopic dermatitis, and urticaria are caused by allergic reactions caused by certain allergens. [0003] In the skin drug delivery system, the skin is the main barrier for drugs to enter the body. Studies have found that only a few drugs have excellent skin permeability, and most drugs are not easy to pass through the effective and selective barrier of human skin. Drugs with higher solubility cross the epidermis more easily. In the treatment of skin diseases, the most common type of preparation is transdermal drug delivery, transdermal drug delivery system or transdermal drug delivery system (transderma...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K47/16A61K47/26A61P17/00
Inventor 孙亮陈松赵琳
Owner TIANJIN JINYAO GRP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products